OSE Immunotherapeutics SA
PAR:OSE
Income Statement
Earnings Waterfall
OSE Immunotherapeutics SA
Income Statement
OSE Immunotherapeutics SA
| Dec-2014 | Jun-2015 | Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Sep-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
4
|
3
|
3
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
+900%
|
0
+857%
|
3
+733%
|
7
+109%
|
24
+266%
|
24
+0%
|
20
-19%
|
26
+31%
|
16
-39%
|
10
-34%
|
14
+30%
|
22
+64%
|
26
+18%
|
42
+60%
|
18
-56%
|
4
-80%
|
2
-38%
|
83
+3 647%
|
83
0%
|
2
-97%
|
|
| Gross Profit | ||||||||||||||||||||||||
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
9
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||
| Operating Expenses |
(3)
|
(5)
|
(5)
|
(15)
|
(17)
|
(15)
|
(19)
|
(20)
|
(20)
|
(21)
|
(27)
|
(28)
|
(29)
|
(37)
|
(49)
|
(43)
|
(53)
|
(37)
|
(33)
|
(26)
|
(29)
|
(40)
|
(38)
|
|
| Selling, General & Administrative |
(1)
|
(2)
|
(3)
|
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(4)
|
(5)
|
(5)
|
(6)
|
(7)
|
(9)
|
(12)
|
(12)
|
(14)
|
(9)
|
(9)
|
(7)
|
(8)
|
(9)
|
(10)
|
|
| Research & Development |
(2)
|
(3)
|
(3)
|
(4)
|
(8)
|
(13)
|
(19)
|
(20)
|
(20)
|
(21)
|
(25)
|
(25)
|
(28)
|
(33)
|
(41)
|
(34)
|
(41)
|
(30)
|
(28)
|
(24)
|
(24)
|
(33)
|
(33)
|
|
| Depreciation & Amortization |
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(3)
|
(4)
|
(3)
|
(4)
|
(4)
|
(2)
|
(3)
|
(3)
|
|
| Other Operating Expenses |
0
|
0
|
1
|
(8)
|
(6)
|
2
|
4
|
5
|
5
|
4
|
4
|
4
|
6
|
6
|
6
|
5
|
6
|
6
|
8
|
10
|
4
|
5
|
9
|
|
| Operating Income |
(3)
N/A
|
(5)
-76%
|
(5)
-9%
|
(15)
-171%
|
(17)
-15%
|
(12)
+28%
|
(13)
-4%
|
5
N/A
|
5
-2%
|
(1)
N/A
|
(1)
0%
|
(12)
-747%
|
(19)
-52%
|
(23)
-24%
|
(26)
-12%
|
(16)
+38%
|
(11)
+34%
|
(18)
-70%
|
(29)
-60%
|
(23)
+20%
|
54
N/A
|
44
-19%
|
(35)
N/A
|
|
| Pre-Tax Income | ||||||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(1)
|
1
|
0
|
1
|
(0)
|
(5)
|
(5)
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
34
|
34
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
0
|
(0)
|
|
| Total Other Income |
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
(1)
|
|
| Pre-Tax Income |
(3)
N/A
|
(5)
-81%
|
(6)
-9%
|
20
N/A
|
18
-11%
|
(12)
N/A
|
(13)
-5%
|
5
N/A
|
5
+0%
|
(1)
N/A
|
(1)
-5%
|
(13)
-765%
|
(19)
-52%
|
(24)
-24%
|
(27)
-11%
|
(17)
+35%
|
(10)
+40%
|
(18)
-75%
|
(28)
-55%
|
(23)
+17%
|
50
N/A
|
40
-20%
|
(36)
N/A
|
|
| Net Income | ||||||||||||||||||||||||
| Tax Provision |
(0)
|
0
|
(0)
|
2
|
3
|
2
|
2
|
0
|
1
|
(1)
|
(3)
|
4
|
3
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(2)
|
1
|
|
| Income from Continuing Operations |
(3)
|
(5)
|
(6)
|
22
|
21
|
(10)
|
(11)
|
5
|
5
|
(3)
|
(5)
|
(8)
|
(17)
|
(25)
|
(28)
|
(17)
|
(10)
|
(18)
|
(28)
|
(23)
|
46
|
37
|
(35)
|
|
| Net Income (Common) |
(3)
N/A
|
(5)
-81%
|
(6)
-9%
|
22
N/A
|
21
-6%
|
(10)
N/A
|
(11)
-3%
|
5
N/A
|
5
+16%
|
(3)
N/A
|
(5)
-62%
|
(8)
-78%
|
(17)
-100%
|
(25)
-51%
|
(28)
-11%
|
(17)
+39%
|
(7)
+56%
|
(18)
-142%
|
(28)
-56%
|
(23)
+17%
|
46
N/A
|
37
-19%
|
(35)
N/A
|
|
| EPS (Diluted) |
-0.36
N/A
|
-0.56
-56%
|
-0.59
-5%
|
1.87
N/A
|
1.65
-12%
|
-0.71
N/A
|
-0.73
-3%
|
0.3
N/A
|
0.38
+27%
|
-0.19
N/A
|
-0.31
-63%
|
-0.55
-77%
|
-1.06
-93%
|
-1.38
-30%
|
-1.5
-9%
|
-0.93
+38%
|
-0.39
+58%
|
-0.96
-146%
|
-1.46
-52%
|
-1.18
+19%
|
1.83
N/A
|
1.71
-7%
|
-1.59
N/A
|
|